Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo prospectivo, multicêntrico e não intervencionista para investigar a eficácia do REKOVELLE® para estimulação ovariana em mulheres asiáticas em ambientes do mundo real (PROFOUND)

29 de setembro de 2026 atualizado por: Ferring Pharmaceuticals

Estudo prospectivo, multinacional e não intervencionista para investigar REKOVELLE para estimulação ovariana: a eficácia, segurança e padrões de uso para mulheres asiáticas na prática do mundo real

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Observacional

Inscrição (Real)

1526

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Busan, Coréia do Sul, 47245
        • Ferring Investigational Site
      • Seoul, Coréia do Sul, 02586
        • Maria Fertility Hospital
    • Busan
      • Busan, Busan, Coréia do Sul, 49241
        • Ferring Investigational Site
    • Daegu
      • Daegu, Daegu, Coréia do Sul, 41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si, Seongnam, Coréia do Sul, 13496
        • Ferring Investigational Site
      • Hiroshima, Japão, 7300035
        • Ferring Investigational Site
      • Hokkaido, Japão, 0600003
        • Ferring Investigational Site
      • Hyōgo, Japão, 6500021
        • Ferring Investigational Site
      • Osaka, Japão, 5300011
        • Ferring Investigational Site
      • Osaka, Japão, 5500015
        • Ferring Investigational Site
      • Saitama, Japão, 3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba, Chiba, Japão, 2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japão, 8120013
        • Ferring Investigational Site
      • Kitakyushu, Fukuoka, Japão, 8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki, Gunma, Japão, 3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japão, 7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City, Japan, Japão, 1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo, Tokyo, Japão, 1600023
        • Ferring Investigational Site
      • Bangkok, Tailândia, 10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok, Muang, Tailândia, 65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok, Ratchathewi, Tailândia, 10400
        • Ramathibodi Hospital
      • Taichung, Taiwan, 406
        • Ferring Investigational Site
      • Taipei, Taiwan, 100225
        • Ferring Investigational Site
      • Taipei, Taiwan, 110
        • Ferring Investigational Site
    • Tainan
      • Tainan, Tainan, Taiwan, 70403
        • Ferring Investigational Site
      • Tainan, Tainan, Taiwan, 71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan, Taoyuan, Taiwan, 333
        • Ferring Investigational Site
    • Hanoi
      • Hanoi, Hanoi, Vietnã, 100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnã, 700000
        • Ferring Investigational Site
      • Ho Chi Minh City, Ho Chi Minh City, Vietnã
        • Ferring Investigational Site
    • Huế
      • Huế, Huế, Vietnã, 49000
        • Ferring Investigational Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

N/D

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra de Probabilidade

População do estudo

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Descrição

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Cumulative live birth rate
Prazo: Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The Luteinising hormone (LH) surge suppression protocol
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
Prazo: Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
Prazo: Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
Prazo: Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
Prazo: Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
Prazo: Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
Prazo: Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
Prazo: Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
Prazo: Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Prazo: 11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
Prazo: 4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
Prazo: 4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
Prazo: 9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
Prazo: 4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
Prazo: More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
Prazo: 4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
Prazo: Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Prazo: Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
Prazo: Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
Prazo: Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Prazo: Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Prazo: Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Prazo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Prazo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Prazo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Global Clinical Compliance, Ferring Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de agosto de 2024

Conclusão Primária (Estimado)

1 de maio de 2027

Conclusão do estudo (Estimado)

1 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

6 de agosto de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de agosto de 2024

Primeira postagem (Real)

20 de agosto de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 000430

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever